Concepedia

Author

Masaru Samura

Keio UniversityORCID

Also Known As

M Samura, Masaru Samura, P Conteh

32

Publications

360

Citations

11

H-Index

19

Concepts

All Affiliations

Keio UniversityYokohama University of PharmacyNational Institute for Medical ResearchMwanza Intervention Trials UnitJanssen (Belgium)
MS

About

Masaru Samura is an author at Keio University specializing in medicine, emerging infectious diseases, and vaccine safety.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

131

2

Epidemiology

1

1

89

3

Microbiology

1

1

25

4

Nephrology

1

1

17

5

Pharmacology

1

1

17

Masaru Samura

×

7

Publications

190

Citations

7

H-Index

YearCitations

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Muhammed O. Afolabi, David Ishola, Daniela Manno,

The Lancet Infectious Diseases

2021

89

Support for fungal infection treatment mediated by pharmacist-led antifungal stewardship activities

Masaru Samura, Naoki Hirose, Takenori Kurata,

Journal of Infection and Chemotherapy

2019

25

Population Pharmacokinetic Analysis and Dosing Optimization Based on Unbound Daptomycin Concentration and Cystatin C in Nonobese Elderly Patients with Hypoalbuminemia and Chronic Kidney Disease

Masaru Samura, Keisuke Takada, Risako Yamamoto,

Pharmaceutical Research

2021

17

Model‐informed precision dosing of vancomycin for rapid achievement of target area under the concentration‐time curve: A simulation study

Kazutaka Oda, Tomoyuki Yamada, Kazuaki Matsumoto,

Clinical and Translational Science

2023

17

Identification of Risk Factors for Daptomycin-Associated Creatine Phosphokinase Elevation and Development of a Risk Prediction Model for Incidence Probability

Masaru Samura, Naoki Hirose, Takenori Kurata,

Open Forum Infectious Diseases

2021

16

Relationship between nephrotoxicity and area under the concentration–time curve of vancomycin in critically ill patients: a multicenter retrospective study

Tomoyuki Ishigo, Kazuaki Matsumoto, Hiroaki Yoshida,

Microbiology Spectrum

2024

14

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

E Choi, Boris Lacarra, Muhammed O. Afolabi,

The Lancet Global Health

2023

12

Page 1